Inhibikase Therapeutics Inc. (IKT)
NASDAQ · Healthcare
Inhibikase Therapeutics Inc. annual/quarterly total liabilities history from 2020 to 2024. Total liabilities is the combined debt and financial obligations a company owes to creditors.
- Inhibikase Therapeutics Inc. total liabilities for the quarter ending December 31, 2024 were 3.7M, a 5.80% increase year-over-year.
- Inhibikase Therapeutics Inc. total liabilities for 2024 were 3.7M, a 5.80% increase from 2023.
- Inhibikase Therapeutics Inc. total liabilities for 2023 were 3.5M, a 9.54% decrease from 2022.
- Inhibikase Therapeutics Inc. total liabilities for 2022 were 3.9M, a 3.79% decrease from 2021.
- Inhibikase Therapeutics Inc. total liabilities for 2021 were 4.1M.
Total Liabilities
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| Inhibikase Therapeutics Inc. Annual Total Liabilities (Millions of US $) | |
|---|---|
| 2024 | $4 |
| 2023 | $4 |
| 2022 | $4 |
| 2021 | $4 |
| 2020 | $5 |
| Inhibikase Therapeutics Inc. Quarterly Total Liabilities (Millions of US $) | |
|---|---|
| 2024-12-31 | $4 |
| 2023-12-31 | $4 |
| 2022-12-31 | $4 |
| 2021-12-31 | $4 |
| 2020-12-31 | $5 |
Inhibikase Therapeutics Inc. Total Liabilities — FAQ
Inhibikase Therapeutics Inc. (IKT) total liabilities over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IKT's total liabilities history?
The chart and table above show Inhibikase Therapeutics Inc.'s total liabilities by year and by quarter, including the growth rate.